ESALF News and Press, Eisai Co Ltd From 09/22/23

2023-09-22 16:01:40 ET Summary Eisai Co., Ltd. has experienced a sharp decline amid lumpy progress with its Alzheimer's disease drug, Leqembi. Q1 FY'23 numbers show modest growth in ESALF's pharmaceutical business, but revenue and operating income have decreased over time. ESA...

2023-09-22 08:32:33 ET More on Merck Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump? Merck granted FDA pri...

Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21 TOKYO, Sept 21, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story"...

Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem TOKYO, Sept 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technolo...

2023-08-23 14:09:18 ET More on Biogen Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher? Seeking Alpha’s Quant Rating on Biogen For further details see: Biogen's Leqembi set for ...

2023-08-08 10:26:14 ET Shares of Eli Lilly ( NYSE: LLY ) hit an all-time high of $534.41 Tuesday morning, with the pharma briefly surpassing the $500B market cap mark. Q2 earnings beats combined with a bullish full-year outlook that prompted guidance boosts are responsible f...

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment TOKYO, Aug 4, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initi...

2023-07-25 10:22:46 ET Summary Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. The companies recast the data to suggest non-carriers benefitted more from their drugs, but in reality, non-carriers benefitted least as ...

2023-07-25 08:26:12 ET Biogen ( NASDAQ: BIIB ) exceeded Wall Street forecasts with its Q2 2023 results on Tuesday and announced a new cost savings program including plans to reduce about 1,000 employees as the company shifts its resources to newly approved medications. The C...

2023-07-24 15:08:24 ET Summary Eli Lilly and Company's share price won't stop climbing on the promise of its "miracle" diabetes and weight loss drug, Tirzepatide, and franchise. The share price is +25% so far this year, and +425% over a 5-year period. Lilly is now the world's most...